ASH 2023 | 5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the 5-year follow-up of patients treated with ibrutinib plus venetoclax as first-line treatment for chronic lymphocytic leukemia (CLL) in a Phase II trial. The data revealed that ~70% of patients achieved undetectable measurable residual disease (uMRD) in bone marrow and the 5-year progression-free survival (PFS) exceeded 90%, establishing this combination therapy as an effective option for reaching durable remission. Additionally, those patients who relapsed following treatment were effectively retreated with BTK inhibitors. The trial is ongoing with clinical data expected to be presented next year. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Cellectis, TG Therapeutics, Genentech, Beigene, CareDX, Ipsen, MEI Pharma, Janssen, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
Honoraria: AbbVie, Cellectis, TG Therapeutics, Genentech, Beigene, CareDX, Ipsen, MEI Pharma, Janssen, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
Other (Travel, Accommodation, Expenses): AbbVie, Cellectis, TG Therapeutics, Genentech, Beigene, CareDX, Ipsen, MEI Pharma, Janssen, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
Research Funding: AbbVie, Cellectis, Takeda, Genentech, ADC Therapeutics, Servier, TransThera Sciences, Mingsight, Aprea Therapeutics, Medisix, Incyte, Newave, Fate Therapeutics, Dialectic Therapeutics, Novalgen, Loxo Oncology, Pfizer, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
